After a kidney transplant, BK virus can reactivate under immunosuppression and threaten the graft. SPyDiag’s aim is to make screening more accessible and to open a specific therapeutic route — two levers on the same problem.
Simplifying BK virus monitoring to better protect the graft
BK virus follow-up conventionally depends on tests that require laboratory organisation: instruments, trained staff, batched runs. SPyDiag’s approach is oriented towards the point of care instead — make screening simple enough to do it more often, and shorten the delay between a signal and a clinical decision.
The reasoning is straightforward. Roughly 40% of kidney transplant recipients develop asymptomatic viruria, around 20% develop viremia, and up to 10% develop BK virus nephropathy. Urinary replication precedes viremia, which precedes tubulointerstitial injury. The earlier in that sequence a signal is caught, the more room the clinical team has to act.
UriFastBK: reflex screening, more often
UriFastBK is a rapid urinary lateral flow test designed to detect viral particles by targeting the VP1 capsid protein of BKPyV, delivering a result usable for triage and orientation.
- Clinically — it supports more frequent surveillance without systematically mobilising a molecular platform.
- For the pathway — it brings the team’s attention forward, with confirmation and management following protocol.
- For the patient — follow-up that is potentially smoother and better integrated into daily life.
The point worth holding onto is that a rapid urinary test can raise screening frequency and shorten the interval between signal and action — which is precisely what the high-risk window after transplantation calls for.
Published analytical and clinical data are set out on the UriFastBK data page.
BKNeutrol: a specific therapeutic ambition
BKNeutrol is an immunotherapy programme based on a bispecific antibody directed against VP1, with the objective of a treatment specifically targeting BK virus. The project has passed in vitro proof of concept; the next step is regulatory toxicity evaluation ahead of phase I trials.
| Parameter | Programme |
|---|---|
| Target | VP1, BKPyV capsid protein |
| Stated coverage | Genotypes I and IV, the dominant strains |
| Format | Bispecific antibody |
| Objective | Reduce the risk of graft loss without lowering immunosuppression |
To date, no specific treatment for BK virus has been approved. Several monoclonal antibody programmes targeting VP1 are in clinical development elsewhere, which makes the target itself well validated — and the competitive position clear.
What this could look like in practice
- More accessible screening — simpler means more frequent, which means earlier detection of signals compatible with reactivation.
- A more responsive pathway — rapid triage, then confirmation and therapeutic adjustment according to centre standards.
- A more complete strategy — pairing diagnosis with a specific therapeutic approach could shift the current balance, which today rests largely on adjusting immunosuppression.
- Patient impact — follow-up that is anticipated rather than endured, with one clear objective: protecting the graft and quality of life.
Frequently asked questions
Why is this approach described as innovative?
Because it aims to simplify screening through a rapid urinary test, making it potentially more frequent and therefore more responsive, and because it also carries a specific therapeutic ambition.
Does UriFastBK replace PCR or hospital follow-up?
No. The logic is complementary: a rapid test assists triage and orientation, while reference testing and therapeutic decisions remain with the transplant team.
Is BKNeutrol an available treatment?
No. It is an immunotherapy programme in development, with preclinical and regulatory steps ahead. Availability will depend on those validations and on clinical trials.
What should one watch to follow progress?
Three things: clinical validation of urinary screening, real-world performance data, and regulatory and clinical progress of the therapeutic programme.
Informational content. It does not replace the advice of a healthcare professional.